The manufacturers of Ozempic and Mounjaro are creating oral weight loss medications that could change treatment methods. These daily pills, pending FDA approval, reportedly show significant results in ...

Novo Nordisk A/S (NVO), though cheap at 13x forward earnings, is in my view a value trap, as growth is slowing and GLP-1 ...

Novo Nordisk’s closest rival is Eli Lilly, whose GLP-1 drugs have also posted strong demand. A softer read on IRA discounts ...

Eli Lilly announced trial results for its weight-loss medication, orforglipron, in August. Orforglipron is a once-daily oral ...

Eli Lilly and Novo Nordisk have announced they are working on new oral drugs that can be used for type-2 diabetes and weight ...

Discover the revolutionary needle-free weight-loss pill orforglipron, often referred to as 'Ozempic 2.0'. Learn how it ...

Does berberine offer a natural alternative to medications like Ozempic, as many users on social media claim? “Berberine has ...

Marketers are positioning weight-loss shots as cosmetic elixirs for anyone who wants to lose a few pounds. Doctors warn that ...

And Big Pharma’s not done cashing in on the weight-loss boom. Drugmakers are readying a new wave of next-level GLP-1 ...

Semaglutide does influence processes linked to Alzheimer’s, but these trials suggest it does not slow symptoms once they ...

Diabetes and weight loss drug semaglutide has been trialled in people with Alzheimer's. We explain what it means for dementia ...

OneSource anticipates leading the generics market for semaglutide as multiple patents expire, expanding its capacity and ...